Return to Work in Patients with Hematological Cancers 1 Year after Treatment: A Prospective Longitudinal Study
Standard
Return to Work in Patients with Hematological Cancers 1 Year after Treatment: A Prospective Longitudinal Study. / Hartung, Tim J; Sautier, Leon P; Scherwath, Angela; Sturm, Kirsten; Kröger, Nicolaus; Koch, Uwe; Mehnert, Anja.
In: ONCOL RES TREAT, Vol. 41, No. 11, 2018, p. 697-701.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Return to Work in Patients with Hematological Cancers 1 Year after Treatment: A Prospective Longitudinal Study
AU - Hartung, Tim J
AU - Sautier, Leon P
AU - Scherwath, Angela
AU - Sturm, Kirsten
AU - Kröger, Nicolaus
AU - Koch, Uwe
AU - Mehnert, Anja
N1 - © 2018 S. Karger GmbH, Freiburg.
PY - 2018
Y1 - 2018
N2 - BACKGROUND: Although hematological cancer survivors have a high risk of disability, data on work-related issues are scarce for this population.METHODS: We investigated return to work (RTW) and work ability (Work Ability Index, WAI) in hematological cancer patients 6 months and 1 year after cancer treatment. We explored associations between baseline sociodemographic and medical characteristics and RTW as well as work ability at follow-up.RESULTS: The participation rate was 42% (baseline n = 91, after 12 months n = 40 (44%)). 6 months after cancer treatment, 33% (95% confidence interval 21%-46%) of the remaining patients had returned to work. After 12 months, the RTW rate was 58% (42%-73%). Mean WAI sum score ± SD significantly increased from 18.5 ± 7.3 at baseline to 28.3 ± 8.3 after 12 months (p = 0.001). Patients with lymphoma (r = 0.31, p = 0.02) and patients who received radiation therapy (r = 0.29, p = 0.04) were significantly more likely to return to work. Work ability after 6 months was most strongly associated with higher education (r = 0.60, p < 0.01). Patients' subjective prognosis of gainful employment before cancer treatment predicted work ability after 6 (r = 0.62, p < 0.01) and 12 months (r = 0.51, p < 0.01).CONCLUSION: The chance of returning to work of hematological malignancy survivors is similar to that of other cancer patients.
AB - BACKGROUND: Although hematological cancer survivors have a high risk of disability, data on work-related issues are scarce for this population.METHODS: We investigated return to work (RTW) and work ability (Work Ability Index, WAI) in hematological cancer patients 6 months and 1 year after cancer treatment. We explored associations between baseline sociodemographic and medical characteristics and RTW as well as work ability at follow-up.RESULTS: The participation rate was 42% (baseline n = 91, after 12 months n = 40 (44%)). 6 months after cancer treatment, 33% (95% confidence interval 21%-46%) of the remaining patients had returned to work. After 12 months, the RTW rate was 58% (42%-73%). Mean WAI sum score ± SD significantly increased from 18.5 ± 7.3 at baseline to 28.3 ± 8.3 after 12 months (p = 0.001). Patients with lymphoma (r = 0.31, p = 0.02) and patients who received radiation therapy (r = 0.29, p = 0.04) were significantly more likely to return to work. Work ability after 6 months was most strongly associated with higher education (r = 0.60, p < 0.01). Patients' subjective prognosis of gainful employment before cancer treatment predicted work ability after 6 (r = 0.62, p < 0.01) and 12 months (r = 0.51, p < 0.01).CONCLUSION: The chance of returning to work of hematological malignancy survivors is similar to that of other cancer patients.
KW - Journal Article
U2 - 10.1159/000491589
DO - 10.1159/000491589
M3 - SCORING: Journal article
C2 - 30317227
VL - 41
SP - 697
EP - 701
JO - ONCOL RES TREAT
JF - ONCOL RES TREAT
SN - 2296-5270
IS - 11
ER -
